View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 28, 2019

Sun Pharma and CMS to commercialise CsA eye drops in China

A subsidiary of Sun Pharmaceutical Industries has signed an agreement with a China Medical System (CMS) subsidiary to develop and commercialise Cyclosporine A 0.09% (CsA) eye drops.

A subsidiary of Sun Pharmaceutical Industries has signed an agreement with a China Medical System (CMS) subsidiary to develop and commercialise Cyclosporine A 0.09% (CsA) eye drops.

Indicated for dry eye disease, CsA will be commercialised in Greater China, including parts of Hong Kong, Macao and Taiwan.

Under the 15-year exclusive licensing agreement, CMS will pay an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales to Sun Pharma.

In return, Sun Pharma will be responsible for the development, regulatory filings and commercialisation of CsA in China.

The agreement tenure has an option to be extended for an additional three years subject to certain conditions defined in the agreement.

Sun Pharma executive vice-president and global business development head Kirti Ganorkar said: “We are pleased to enter into a licensing arrangement with CMS, a leading pharmaceutical company in Greater China.

“Dry Eye disease represents an area of high unmet medical need, with a significant number of patients having moderate to severe form of this disease. Sun Pharma is committed to growing its global ophthalmology franchise, with cyclosporine as its lead product.”

Following the purchase of Ocular Technologies, CMS acquired global rights and intellectual property for CsA ophthalmic solution. In August last year, the US Food and Drug Administration (FDA) approved the solution under the CEQUA brand name.

Last November, Sun Pharma signed a definitive agreement to acquire Japan-based Pola Pharma, which is engaged in the research, development, manufacture and sale of branded and generic products.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology